Lentiviral Vector Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The lentiviral vector market size has grown rapidly in recent years. It will grow from $14.37 billion in 2024 to $16.62 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth in the historic period can be attributed to prevalence of genetic disorders, gene delivery demand, biotech and pharma expansion, clinical trial investment, regulatory approvals.

The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $29.41 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%. The growth in the forecast period can be attributed to personalized medicine growth, gene editing innovations, rare disease therapy demand, lentiviral vector adoption, genomic medicine funding, manufacturing scalability focus. Major trends in the forecast period include expansion of research and development, integration in CAR-T cell therapy, development of next-generation vectors, adoption in vaccine development, development of production technologies.

The rising prevalence of chronic diseases is expected to drive the growth of the lentiviral vectors market. Chronic diseases are long-term health conditions that develop gradually and persist for years or even a lifetime. The increasing prevalence of these diseases is attributed to factors such as aging populations, unhealthy lifestyles, urbanization, and environmental influences. Lentiviral vectors provide versatile and efficient tools for developing vaccines and treatment strategies for chronic diseases, addressing unmet medical needs and improving patient outcomes. For instance, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, with 4 million males and 3.6 million females living with these conditions. These diseases are responsible for around 27% of all deaths in the UK, leading to over 170,000 deaths annually, or about 480 deaths per day - roughly one death every three minutes. Thus, the increasing prevalence of chronic diseases is driving the growth of the lentiviral vectors market.

Key players in the lentiviral vectors market are concentrating their efforts on advancing LV vector production platforms to enhance the efficiency and robustness of lentivirus vector manufacturing for cell-based immuno-oncology therapies. One such innovative platform is LentiSure, designed to optimize the production of lentiviral vectors for cell-based immuno-oncology therapies. Launched by Yposkesi sk pharmteco in May 2023, LentiSure aims to bolster the resilience and efficiency of lentivirus production, catering to the escalating demand for scalable and reliable viral vector manufacturing technologies in cell and gene therapies. With features such as consistent product quality and high productivity, LentiSure offers promise in accelerating the development and commercialization of cell-based immuno-oncology therapies, addressing the unmet medical needs associated with chronic diseases.

In September 2024, Kyverna Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, entered into a license and supply agreement for the LentiVector platform with Oxford Biomedica. This collaboration allows Kyverna to utilize Oxford Biomedica’s proprietary lentiviral vector technology in the development of gene therapies, particularly targeting autoimmune diseases. The agreement supports the expansion and innovation of the lentiviral vector market by ensuring a scalable and reliable supply of vectors to meet the growing demand. Oxford Biomedica is a UK-based biotechnology company specializing in providing lentiviral vector platforms.

Major companies operating in the lentiviral vector market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Agilent Technologies Inc., Amgen Inc., Merck KGaA, Lonza Group Ag, Cytiva, Charles River Laboratories, Bio-Rad Laboratories Inc., Promega Corporation, Takara Bio Inc., Sino Biological Inc., OriGene Technologies Inc., Applied Biological Materials Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi.

North America was the largest region in the lentiviral vector market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lentiviral vector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

A lentiviral vector is a viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of host cells. These vectors are widely used in molecular biology and gene therapy applications to deliver genetic material into target cells for purposes such as gene expression, gene silencing, or genetic modification.

Key products in the lentiviral vector category include kits, reagents, and consumables. Lentiviral vector kits provide a comprehensive set of tools and components necessary for generating and manipulating lentiviral vectors. These kits find application across various indications such as cancer, genetic disorders, infectious diseases, veterinary diseases, and more. Users of lentiviral vector products include biotechnology companies, pharmaceutical companies, contract research organizations (CROs), as well as academic and research institutes.

The lentiviral vector market research report is one of a series of new reports that provides lentiviral vector market statistics, including lentiviral vector industry global market size, regional shares, competitors with a lentiviral vector market share, detailed lentiviral vector market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. This lentiviral vector market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.